Health Policy

Raw citation data, Impact Factor, Immediacy Index, Published documents, Citations received, , Most cited papers , Latest citations and documents published in this series in EconPapers.

Raw data:
IF AIF DOC CIT D2Y C2Y SC(%) CiY II AII 1996 0.01 0.17 75 31 171 2 0 0.08 1997 0.01 0.2 92 25 163 1 0 0.08 1998 0.01 0.23 55 29 167 1 0 0.1 1999 0.05 0.32 60 36 147 7 0 0.16 2000 0.04 0.43 60 32 115 5 0 0.19 2001 0.05 0.39 64 25 120 6 0 0.17 2002 0.04 0.42 75 19 124 5 0 0.2 2003 0.03 0.47 104 28 139 4 0 0.22 2004 0.03 0.51 125 28 179 5 0 2 0.02 0.23 2005 0.04 0.58 136 15 229 10 0 4 0.03 0.27
IF: Impact Factor: C2Y / D2Y AIF: Average Impact Factor for series in RePEc in year y DOC: Number of documents published in year y CIT: Number of citations to the series in year y D2Y: Number of articles published in y-1 plus y-2 C2Y: Cites in y to articles published in y-1 plus y-2 SC(%): Percentage of selft citations in y to articles published in y-1 plus y-2 CiY: Cites in year y to documents published in year y IdI: Immediacy Index: CiY / Documents.   AII: Average Immediacy Index for series in RePEc in year y
Impact Factor:
Immediacy Index:
Documents published:
Citations received:

Most cited documents in this series:

(1) RePEc:eee:hepoli:v:47:y:1999:i:2:p:97-123 The contingent valuation method in health care (1999).
Cited: 24 times.

(2) RePEc:eee:hepoli:v:54:y:2000:i:2:p:87-123 Review of the literature on reference pricing (2000).
Cited: 11 times.

(3) RePEc:eee:hepoli:v:37:y:1996:i:1:p:53-72 EuroQol: the current state of play (1996).
Cited: 11 times.

(4) RePEc:eee:hepoli:v:24:y:1993:i:3:p:227-238 The trade-off between severity of illness and treatment effect in cost-value analysis of health care (1993).
Cited: 10 times.

(5) RePEc:eee:hepoli:v:63:y:2003:i:1:p:17-36 The economic impact of malaria in Africa: a critical review of the evidence (2003).
Cited: 8 times.

(6) RePEc:eee:hepoli:v:67:y:2004:i:2:p:149-165 Incentives and pharmaceutical reimbursement reforms in Spain (2004).
Cited: 6 times.

(7) RePEc:eee:hepoli:v:49:y:1999:i:1-2:p:63-74 Public views on health care rationing: a group discussion study (1999).
Cited: 5 times.

(8) RePEc:eee:hepoli:v:34:y:1995:i:2:p:135-143 Value for money? A contingent valuation study of the optimal size of the Swedish health care budget (1995).
Cited: 5 times.

(9) RePEc:eee:hepoli:v:51:y:2000:i:2:p:109-131 An update on Spains health care system: is it time for managed competition? (2000).
Cited: 5 times.

(10) RePEc:eee:hepoli:v:57:y:2001:i:1:p:1-13 Health economics in low income countries: adapting to the reality of the unofficial economy (2001).
Cited: 5 times.

(11) RePEc:eee:hepoli:v:51:y:2000:i:1:p:19-30 A qualitative study of the extent to which health gain matters when choosing between groups of patients (2000).
Cited: 4 times.

(12) RePEc:eee:hepoli:v:40:y:1997:i:3:p:237-255 Household income and health care expenditures in Mexico (1997).
Cited: 4 times.

(13) RePEc:eee:hepoli:v:68:y:2004:i:1:p:47-54 The effect of generic competition on the price of brand-name drugs (2004).
Cited: 4 times.

(14) RePEc:eee:hepoli:v:65:y:2003:i:2:p:167-179 The availability of drugs: what does it mean in Ugandan primary care (2003).
Cited: 4 times.

(15) RePEc:eee:hepoli:v:44:y:1998:i:3:p:233-252 Primary health care meets the market in China and Vietnam (1998).
Cited: 4 times.

(16) RePEc:eee:hepoli:v:57:y:2001:i:2:p:141-153 Scope and scale insensitivities in a contingent valuation study of risk reductions (2001).
Cited: 4 times.

(17) RePEc:eee:hepoli:v:44:y:1998:i:2:p:123-134 Effects of user charges on the use of prescription medicines in different socio-economic groups (1998).
Cited: 4 times.

(18) RePEc:eee:hepoli:v:38:y:1996:i:2:p:117-128 The costs of nursing turnover: evidence from the British National Health Service (1996).
Cited: 4 times.

(19) RePEc:eee:hepoli:v:41:y:1997:i:1:p:1-36 Structured pluralism: towards an innovative model for health system reform in Latin America (1997).
Cited: 4 times.

(20) RePEc:eee:hepoli:v:46:y:1998:i:1:p:21-41 The new pharmaceutical policy in Italy (1998).
Cited: 4 times.

(21) RePEc:eee:hepoli:v:60:y:2002:i:3:p:235-254 Free choice of sickness funds in regulated competition: evidence from Germany and The Netherlands (2002).
Cited: 4 times.

(22) RePEc:eee:hepoli:v:69:y:2004:i:1:p:55-72 Technical efficiency in the use of health care resources: a comparison of OECD countries (2004).
Cited: 4 times.

(23) RePEc:eee:hepoli:v:21:y:1992:i:3:p:249-279 Cost-utility in practice: A policy makers guide to the state of the art (1992).
Cited: 3 times.

(24) RePEc:eee:hepoli:v:57:y:2001:i:2:p:111-139 The potential demand for an AIDS vaccine in Thailand (2001).
Cited: 3 times.

(25) RePEc:eee:hepoli:v:28:y:1994:i:2:p:133-141 Cost-effectiveness ratios: in a league of their own (1994).
Cited: 3 times.

(26) RePEc:eee:hepoli:v:50:y:2000:i:3:p:197-218 Drug cost containment policies in Italy: are they really effective in the long-run?: The case of minimum reference price (2000).
Cited: 3 times.

(27) RePEc:eee:hepoli:v:55:y:2001:i:1:p:51-69 Health-related quality of life by disease and socio-economic group in the general population in Sweden (2001).
Cited: 3 times.

(28) RePEc:eee:hepoli:v:60:y:2002:i:3:p:201-218 Policy relevant determinants of health: an international perspective (2002).
Cited: 3 times.

(29) RePEc:eee:hepoli:v:31:y:1995:i:2:p:103-110 The use of economic evaluation in health care: Australian decision makers perceptions (1995).
Cited: 3 times.

(30) RePEc:eee:hepoli:v:71:y:2005:i:2:p:213-222 Tobacco consumption patterns and its health implications in India (2005).
Cited: 3 times.

(31) RePEc:eee:hepoli:v:35:y:1996:i:3:p:205-216 An epidemiological approach towards measuring the trade-off between equity and efficiency in health policy (1996).
Cited: 3 times.

(32) RePEc:eee:hepoli:v:52:y:2000:i:2:p:129-145 The cost of prescription medicines to patients (2000).
Cited: 3 times.

(33) RePEc:eee:hepoli:v:65:y:2003:i:1:p:21-35 Needs for further improvement: risk adjustment in the German health insurance system (2003).
Cited: 3 times.

(34) RePEc:eee:hepoli:v:20:y:1992:i:3:p:309-320 Economic evaluation of lipid lowering -- A feasibility test of the contingent valuation approach (1992).
Cited: 3 times.

(35) RePEc:eee:hepoli:v:40:y:1997:i:3:p:199-215 The role of economic evaluation in the pricing and reimbursement of medicines (1997).
Cited: 3 times.

(36) RePEc:eee:hepoli:v:58:y:2001:i:1:p:83-96 Policy implications of the inadequate support systems for orphans in Western Kenya (2001).
Cited: 3 times.

(37) RePEc:eee:hepoli:v:34:y:1995:i:2:p:145-151 The efficacy and equity of retransplantation: an experimental survey of public attitudes (1995).
Cited: 3 times.

(38) RePEc:eee:hepoli:v:43:y:1998:i:1:p:33-44 Value measurement in cost-utility analysis: explaining the discrepancy between rating scale and person trade-off elicitations (1998).
Cited: 3 times.

(39) RePEc:eee:hepoli:v:17:y:1991:i:1:p:1-23 Economic evaluation in health care: Is there a role for cost-benefit analysis? (1991).
Cited: 3 times.

(40) RePEc:eee:hepoli:v:60:y:2002:i:2:p:133-150 Reforming Chinas urban health insurance system (2002).
Cited: 3 times.

(41) RePEc:eee:hepoli:v:38:y:1996:i:3:p:155-171 Is community financing necessary and feasible for rural China? (1996).
Cited: 2 times.

(42) RePEc:eee:hepoli:v:51:y:2000:i:2:p:67-85 Health insurance markets and income inequality: findings from an international health policy survey (2000).
Cited: 2 times.

(43) RePEc:eee:hepoli:v:8:y:1987:i:3:p:317-323 Cost of illness studies: An aid to decision-making? (1987).
Cited: 2 times.

(44) RePEc:eee:hepoli:v:44:y:1998:i:2:p:103-122 Economic transition and health transition: comparing China and Russia (1998).
Cited: 2 times.

(45) RePEc:eee:hepoli:v:68:y:2004:i:2:p:197-209 The impact of urban health insurance reform on hospital charges: a case study from two cities in China (2004).
Cited: 2 times.

(46) RePEc:eee:hepoli:v:78:y:2006:i:1:p:77-92 Socioeconomic determinants of regional differences in outpatient antibiotic consumption: Evidence from Switzerland (2006).
Cited: 2 times.

(47) RePEc:eee:hepoli:v:42:y:1997:i:2:p:145-155 The importance of lifestyle to self-assessed health (1997).
Cited: 2 times.

(48) RePEc:eee:hepoli:v:46:y:1998:i:1:p:43-52 Neonatal mortality in the Czech Republic during the transition (1998).
Cited: 2 times.

(49) RePEc:eee:hepoli:v:24:y:1993:i:1:p:9-17 Evaluating the policy role of the small area variations and physician practice style hypotheses (1993).
Cited: 2 times.

(50) RePEc:eee:hepoli:v:43:y:1998:i:3:p:219-232 Controlling antimicrobial resistance: a proposed transferable permit market (1998).
Cited: 2 times.

Latest citations received in: | 2005 | 2004 | 2003 | 2002

Latest citations received in: 2005

(1) RePEc:fda:fdaddt:2005-15 Measuring Changes in Health Capital (2005). FEDEA / Working Papers

(2) RePEc:ind:igiwpp:2005-003 Price elasticity estimates for tobacco and other addictive goods in India (2005). Indira Gandhi Institute of Development Research, Mumbai, India / Indira Gandhi Institute of Development Research, Mumbai Working Papers

(3) RePEc:ssa:lemwps:2005/24 Innovation and Standards in Clinical Practice: The Case of HIV Treatments (2005). Laboratory of Economics and Management (LEM), Sant'Anna School of Advanced Studies, Pisa, Italy / LEM Papers Series

(4) RePEc:wly:hlthec:v:14:y:2005:i:s1:p:s187-s202 The Italian health-care system (2005). Health Economics

Latest citations received in: 2004

(1) RePEc:upf:upfgen:762 Regulatory Ambivalence and the Limitations of Pharmaceutical Policy in Spain (2004). Department of Economics and Business, Universitat Pompeu Fabra / Economics Working Papers

(2) RePEc:upf:upfses:762 Regulatory Ambivalence and the Limitations of Pharmaceutical Policy in Spain (2004). Department of Economics and Business, Universitat Pompeu Fabra / Working Papers, Research Center on Health and Economics

Latest citations received in: 2003

Latest citations received in: 2002

Warning!! This is still an experimental service. The results of this service should be interpreted with care, especially in research assessment exercises. The processing of documents is automatic. There still are errors and omissions in the identification of references. We are working to improve the software to increase the accuracy of the results.

Source data used to compute the impact factor of RePEc series.